Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

John D. McConnell, Jean D. Wilson, Fredrick W. George, Jack Geller, Fran Pappas, Elizabeth Stoner

Research output: Contribution to journalArticle

272 Citations (Scopus)

Abstract

The oral administration of finasteride, a 4-azasteroid inhibitor of 5α-reductase, decreases serum dihydrotestosterone levels, but has little effect on serum testosterone. The current study was designed to assess the effect of finasteride on dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. In a double blind, placebo-controlled study, 69 men with symptomatic prostatic hyperplasia were treated with placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate. In the placebo group the mean concentration of prostatic dihydrotestosterone was 10.3 ± 0.6 nmol/kg (±SE), and the mean concentration of testosterone was 0.7 ± 0.1 nmol/kg. After 7 days of treatment with all doses of finasteride, prostatic dihydrotestosterone declined to 15% or less of control levels, and the testosterone concentration increased in a reciprocal fashion. Compared to the placebo group, there was no significant difference in the mean prostatic dihydrotestosterone level achieved in any of the finasteride-treated groups. However, prostatic dihydrotestosterone levels were lower in the groups receiving higher doses of the drug. In two additional patients, finasteride treatment for 2 days also caused a decrease in prostatic dihydrotestosterone levels. No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.

Original languageEnglish (US)
Pages (from-to)505-508
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume74
Issue number3
StatePublished - Mar 1992

Fingerprint

Finasteride
Dihydrotestosterone
Prostatic Hyperplasia
Oxidoreductases
Placebos
Testosterone
Azasteroids
Patient treatment
Transurethral Resection of Prostate
Level control
Serum
Oral Administration
Prostate

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. / McConnell, John D.; Wilson, Jean D.; George, Fredrick W.; Geller, Jack; Pappas, Fran; Stoner, Elizabeth.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 74, No. 3, 03.1992, p. 505-508.

Research output: Contribution to journalArticle

McConnell, John D. ; Wilson, Jean D. ; George, Fredrick W. ; Geller, Jack ; Pappas, Fran ; Stoner, Elizabeth. / Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. In: Journal of Clinical Endocrinology and Metabolism. 1992 ; Vol. 74, No. 3. pp. 505-508.
@article{eb522a4f1d164f4ab8618ce278cd56e4,
title = "Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia",
abstract = "The oral administration of finasteride, a 4-azasteroid inhibitor of 5α-reductase, decreases serum dihydrotestosterone levels, but has little effect on serum testosterone. The current study was designed to assess the effect of finasteride on dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. In a double blind, placebo-controlled study, 69 men with symptomatic prostatic hyperplasia were treated with placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate. In the placebo group the mean concentration of prostatic dihydrotestosterone was 10.3 ± 0.6 nmol/kg (±SE), and the mean concentration of testosterone was 0.7 ± 0.1 nmol/kg. After 7 days of treatment with all doses of finasteride, prostatic dihydrotestosterone declined to 15{\%} or less of control levels, and the testosterone concentration increased in a reciprocal fashion. Compared to the placebo group, there was no significant difference in the mean prostatic dihydrotestosterone level achieved in any of the finasteride-treated groups. However, prostatic dihydrotestosterone levels were lower in the groups receiving higher doses of the drug. In two additional patients, finasteride treatment for 2 days also caused a decrease in prostatic dihydrotestosterone levels. No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.",
author = "McConnell, {John D.} and Wilson, {Jean D.} and George, {Fredrick W.} and Jack Geller and Fran Pappas and Elizabeth Stoner",
year = "1992",
month = "3",
language = "English (US)",
volume = "74",
pages = "505--508",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

AU - McConnell, John D.

AU - Wilson, Jean D.

AU - George, Fredrick W.

AU - Geller, Jack

AU - Pappas, Fran

AU - Stoner, Elizabeth

PY - 1992/3

Y1 - 1992/3

N2 - The oral administration of finasteride, a 4-azasteroid inhibitor of 5α-reductase, decreases serum dihydrotestosterone levels, but has little effect on serum testosterone. The current study was designed to assess the effect of finasteride on dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. In a double blind, placebo-controlled study, 69 men with symptomatic prostatic hyperplasia were treated with placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate. In the placebo group the mean concentration of prostatic dihydrotestosterone was 10.3 ± 0.6 nmol/kg (±SE), and the mean concentration of testosterone was 0.7 ± 0.1 nmol/kg. After 7 days of treatment with all doses of finasteride, prostatic dihydrotestosterone declined to 15% or less of control levels, and the testosterone concentration increased in a reciprocal fashion. Compared to the placebo group, there was no significant difference in the mean prostatic dihydrotestosterone level achieved in any of the finasteride-treated groups. However, prostatic dihydrotestosterone levels were lower in the groups receiving higher doses of the drug. In two additional patients, finasteride treatment for 2 days also caused a decrease in prostatic dihydrotestosterone levels. No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.

AB - The oral administration of finasteride, a 4-azasteroid inhibitor of 5α-reductase, decreases serum dihydrotestosterone levels, but has little effect on serum testosterone. The current study was designed to assess the effect of finasteride on dihydrotestosterone levels in the prostates of men with benign prostatic hyperplasia. In a double blind, placebo-controlled study, 69 men with symptomatic prostatic hyperplasia were treated with placebo or 1, 5, 10, 50, or 100 mg/day finasteride for 7 days before transurethral resection of the prostate. In the placebo group the mean concentration of prostatic dihydrotestosterone was 10.3 ± 0.6 nmol/kg (±SE), and the mean concentration of testosterone was 0.7 ± 0.1 nmol/kg. After 7 days of treatment with all doses of finasteride, prostatic dihydrotestosterone declined to 15% or less of control levels, and the testosterone concentration increased in a reciprocal fashion. Compared to the placebo group, there was no significant difference in the mean prostatic dihydrotestosterone level achieved in any of the finasteride-treated groups. However, prostatic dihydrotestosterone levels were lower in the groups receiving higher doses of the drug. In two additional patients, finasteride treatment for 2 days also caused a decrease in prostatic dihydrotestosterone levels. No significant adverse experiences occurred during the study. We conclude that finasteride causes profound decrease in prostatic dihydrotestosterone.

UR - http://www.scopus.com/inward/record.url?scp=0026503988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026503988&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 505

EP - 508

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -